Clinical Significance of Serum Squamous Cell Carcinoma Antigen for Patients with Recurrent Esophageal Squamous Cell Carcinoma. 2021

Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, 135-8550, Japan.

BACKGROUND Squamous cell carcinoma antigen (SCC-Ag) is a widely used tumor marker of SCC. However, the clinical significance of serum SCC-Ag levels in recurrent esophageal SCC (ESCC) remains unclear. This study aimed to investigate the clinical relevance of serum SCC-Ag levels in patients with recurrent ESCC after surgery. METHODS This study retrospectively analyzed 208 patients who experienced recurrence after curative resection for ESCC. Serum SCC-Ag levels at the time of recurrence were collected from the patients' records. The patients were classified into tertiles based on the serum SCC-Ag values (low, middle, and high), and the clinical characteristics and outcomes were compared among the groups. RESULTS Significant differences in sex (p = 0.001), pathologic T (p = 0.034), and N stages of primary cancer (p = 0.015) were observed among the groups. Although the recurrence patterns did not differ significantly, a high SCC-Ag was significantly associated with multiple recurrences (p = 0.019). The high-SCC-Ag group patients demonstrated a shorter time to recurrence than the other groups (p = 0.044). The SCC-Ag levels were significantly associated with overall survival after recurrence (p = 0.036). Multivariate analysis showed that serum SCC-Ag value at recurrence was an independent poor prognosticator (p = 0.031). CONCLUSIONS Elevated serum SCC-Ag levels at recurrence were significantly associated with a reduced time to recurrence, multiple recurrences, and a poor prognosis after recurrence. An alternative to the current standard treatment is required to improve the outcome for patients with high serum SCC-Ag levels at recurrence.

UI MeSH Term Description Entries
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077277 Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer. Oesophageal Squamous Cell Carcinoma
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015843 Serpins A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition but differ in their specificity toward proteolytic enzymes. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES. Serpin,Serpin Superfamily,Serpin Peptidase Inhibitors,Serpin Protease Inhibitors,Inhibitors, Serpin Peptidase,Inhibitors, Serpin Protease,Peptidase Inhibitors, Serpin,Protease Inhibitors, Serpin,Superfamily, Serpin

Related Publications

Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
February 2021, Annals of surgical oncology,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
April 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
May 2019, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
April 2020, Translational cancer research,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
July 2004, World journal of surgery,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
November 1985, Nihon Geka Gakkai zasshi,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
January 2023, Frontiers in oncology,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
January 2014, European review for medical and pharmacological sciences,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
June 2011, World journal of gastroenterology,
Yasukazu Kanie, and Akihiko Okamura, and Suguru Maruyama, and Kei Sakamoto, and Daisuke Fujiwara, and Jun Kanamori, and Yu Imamura, and Masayuki Watanabe
May 2016, Archives of medical research,
Copied contents to your clipboard!